Dr. Pamela M. Klein

Since 2008, Dr. Klein has been a principal and founder of PMK BioResearch, a company offering strategic consulting in oncology drug development to corporate boards, management teams, and the investment community. She has also been a venture partner in Ysios Capital Partners, SGIEC, S.A.U. since 2023. She currently serves as a member of the board of directors of several companies including Shasqi and Patrys Ltd., as well as various scientific advisor boards. In 2023, Dr. Klein also joined the board of directors of Frontier Medicines Corp, Ona Therapeutics SL, and Sardona Therapeutics, Inc. Previously, Dr. Klein served on the board of directors of Sardona Therapeutics, Inc., F-Star Therapeutics, Inc. until March 2023, Jiya Acquisition Corp, and Spring Bank Pharmaceuticals, Inc. until its merger with F-Star Therapeutics in July 2020.

Dr. Klein previously spent seven years at the National Cancer Institute as Research Director of the NCI-Navy Breast Center, after which she joined Genentech as Vice President of Development until 2001. She also served as Chief Medical Officer for Intellikine, Inc., which was acquired by Takeda American Holdings.